Amneal Pharmaceuticals (AMRX) announced the U.S. commercial launch of Brekiya injection, the first and only ready-to-use dihydroergotamine, DHE, autoinjector approved for the acute treatment of migraine with or without aura and the acute treatment of cluster headaches in adults. “We are excited to introduce Brekiya autoinjector, making this innovative therapy broadly available to healthcare providers and patients. As the first and only self-administered, ready-to-use DHE autoinjector, Brekiya offers patients the ability to treat debilitating attacks in a convenient way and avoid visits to the emergency room. With our expanding neurology portfolio, Amneal is committed to supporting providers through comprehensive education and ensuring strong patient access as we bring Brekiya autoinjector to market,” said Joe Renda, Senior Vice President, Chief Commercial Officer – Specialty.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMRX:
- Amneal treatment of known or suspected cyanide poisoning granted orphan status
- Amneal Pharmaceuticals announces submission of BLA to U.S. FDA for XOLAIR
- Amneal Pharmaceuticals Positioned for Significant Growth with Strong Product Momentum and Strategic Advantages
- Amneal Pharmaceuticals receives FDA approval for bimatoprost ophthalmic solution
- Amneal Pharmaceuticals price target raised to $14 from $12 at JPMorgan